Rallybio Corp
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RALLYBIO CORPORATION | ||
| Date: March 12, 2024 | By: | /s/ Stephen Uden |
|---|---|---|
| Stephen Uden, M.D. | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Stephen Uden | Chief Executive Officer, President and Director (Principal Executive Officer) | March 12, 2024 |
| Stephen Uden, M.D. | ||
| /s/ Jonathan I. Lieber | Chief Financial Officer and Treasurer (Principal Accounting and Financial Officer) | March 12, 2024 |
| Jonathan I. Lieber | ||
| /s/ Martin W. Mackay | Executive Chairman | March 12, 2024 |
| Martin W. Mackay, Ph.D. | ||
| /s/ Helen M. Boudreau | Director | March 12, 2024 |
| Helen M. Boudreau | ||
| /s/ Wendy K. Chung | Director | March 12, 2024 |
| Wendy K Chung, M.D., Ph.D. | ||
| /s/ Rob Hopfner | Director | March 12, 2024 |
| Rob Hopfner, R.Ph., Ph.D., MBA | ||
| /s/ Ronald M. Hunt | Director | March 12, 2024 |
| Ronald M. Hunt | ||
| /s/ Lucian Iancovici | Director | March 12, 2024 |
| Lucian Iancovici, M.D. | ||
| /s/ Hui Liu | Director | March 12, 2024 |
| Hui Liu, Ph.D. | ||
| /s/ Christine A. Nash | Director | March 12, 2024 |
| Christine A. Nash, MBA | ||
| /s/ Kush M. Parmar | Director | March 12, 2024 |
| Kush M. Parmar, M.D., Ph.D. | ||
| /s/ Paula Soteropoulos | Director | March 12, 2024 |
| Paula Soteropoulos | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Changes in Stockholders' Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.